Best Appetite Suppressants for Women: An Evidence-First Guide

The short answer

For most women who qualify medically, the drugs with the strongest appetite-reducing effect are the newer injectables: Wegovy (semaglutide) and Zepbound (tirzepatide), both FDA-approved specifically for weight management. Older oral options such as phentermine and the combination pills remain useful and are far less expensive, but they fit different situations and time horizons. The right choice depends on your BMI, your other health conditions, whether you use oral birth control, your budget, and what your prescriber judges is safe for you.

This guide compares the prescription options by how they curb appetite, who they suit, and their honest cost structure, then explains why OTC "appetite suppressant" supplements have little quality evidence behind them. Prices for these drugs vary enormously by insurance and program, so this page describes the cost structure rather than quoting a single number, and points you to each manufacturer's own savings page for the live figure.

What an "appetite suppressant" actually means

An appetite suppressant is any agent that reduces hunger or the drive to eat, so you naturally consume fewer calories without white-knuckle willpower. In clinical practice, that effect comes from prescription medications that act on the brain's appetite signals or on gut hormones that tell you when you are full. The over-the-counter products marketed as appetite suppressants, by contrast, are mostly fiber blends, caffeine, or botanical stimulants that do not have the same level of evidence.

NIDDK groups the FDA-approved weight-management medications and notes that most work by making you feel less hungry or full sooner. That is the mechanism buyers are really searching for when they look for a suppressant, so this guide focuses on the approved drugs that produce it, and is honest about the ones that do not.

It matters to separate two questions: does a product reduce appetite, and is it approved and safe for that use? Several of the strongest appetite-reducing drugs are approved only for diabetes, which changes the legal and insurance picture even when the underlying molecule is identical.

The prescription options at a glance (from NIDDK)

The table below summarizes the FDA-approved medications NIDDK lists that reduce appetite, along with how each one works and its approval status. Efficacy varies by person and is not expressed here as a single percentage, because average trial results do not predict any individual woman's response.

Orlistat is included for completeness but is not an appetite suppressant; it blocks the absorption of some dietary fat in the gut, so it belongs to a different category and is listed here only to prevent confusion.

GLP-1 and dual GIP/GLP-1 injections: the strongest appetite effect

Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide) are the two injectables FDA-approved specifically for chronic weight management, and they produce the most pronounced appetite reduction of the current options. Both slow how fast the stomach empties and act on the brain's appetite signaling, so many women report that they simply think about food less and feel full on smaller portions. They are given as a once-weekly self-injection with a pen.

Zepbound works on two gut-hormone receptors (GIP and GLP-1), while Wegovy works on one (GLP-1). That is a mechanistic difference, not a guarantee of a better result for any given person; response and tolerability vary. Both are titrated up slowly over weeks to limit nausea, which is the most common early side effect.

These drugs are intended as long-term treatment for a chronic condition, not a short course. Appetite and weight commonly rebound when the medication is stopped, which is why prescribers frame them as ongoing therapy rather than a quick fix, and why cost over time is a central part of the decision.

Ozempic and Mounjaro: same molecules, different approval

Ozempic contains semaglutide (the same active ingredient as Wegovy) and Mounjaro contains tirzepatide (the same as Zepbound), but Ozempic and Mounjaro are FDA-approved for type 2 diabetes, not weight loss. Prescribing either purely for weight is off-label, which is legal for a licensed clinician to do but affects insurance coverage and manufacturer savings eligibility.

Because the molecules are identical, the appetite-reducing effect is comparable, which is why these diabetes brands are so widely discussed for weight. The practical differences are regulatory and financial: the weight-specific brands (Wegovy, Zepbound) are the on-label choice for weight management, and their manufacturer savings programs are built around that use.

If a provider recommends a diabetes-branded product for weight, ask why, and understand that off-label status can change what your insurer will pay and which savings card you qualify for.

Phentermine and the oral combinations: lower cost, different fit

Phentermine is a stimulant appetite suppressant that has been used for decades and is inexpensive as a generic. Its FDA approval is for short-term use, typically a few weeks, which makes it a poor match for a condition that behaves chronically but a reasonable option for a defined jump-start under supervision. Because it is a stimulant, it is generally avoided in people with uncontrolled high blood pressure, heart disease, or certain anxiety conditions.

Phentermine-topiramate (Qsymia) pairs the appetite-suppressing stimulant with a low dose of an anticonvulsant that reduces cravings and increases fullness, and it is approved for long-term weight management. Topiramate carries a known risk of birth defects, so pregnancy must be excluded before starting and reliable contraception is required during use, a particularly important consideration for women of reproductive age.

Naltrexone-bupropion (Contrave) acts on the brain's appetite and reward pathways and is an oral option for people who prefer a pill and are not candidates for a stimulant. It is not recommended alongside opioids and has its own set of cautions, so the choice among these oral drugs is highly individual.

Who qualifies: the FDA BMI criteria

The FDA labels for the weight-management drugs print the eligibility criteria in the Indications section, and they are consistent across the class. You generally qualify with a body mass index of 30 or higher (the clinical threshold for obesity), or a BMI of 27 or higher (overweight) if you also have at least one weight-related health condition such as high blood pressure, type 2 diabetes, or abnormal cholesterol.

These thresholds are the starting point, not the whole decision. A prescriber weighs your full medical history, current medications, pregnancy status and plans, mental health history, and prior experience with weight treatment before recommending any specific drug.

If your BMI is below these cutoffs, the FDA-approved weight drugs are not indicated for you, and a legitimate telehealth provider should say so rather than prescribing anyway. A provider willing to skip eligibility screening is a warning sign, not a convenience.

Women-specific considerations that change the choice

One difference matters specifically for women who use oral contraception: the tirzepatide label warns that the drug can reduce the effectiveness of oral birth control, and advises a backup or non-oral method around the time of starting and dose increases. Semaglutide does not carry this warning. If you rely on the pill, this is a concrete reason to discuss tirzepatide versus semaglutide with your prescriber.

Topiramate, part of the Qsymia combination, is associated with birth defects, so it is not appropriate if you are pregnant or planning pregnancy, and it requires reliable contraception during use. None of these medications are for use during pregnancy, and GLP-1 drugs are generally stopped before a planned pregnancy on the timeline your prescriber advises.

Weight gain around perimenopause and menopause is a common reason women look for appetite help. Menopause hormone therapy is not a weight-loss treatment; ACOG describes hormone therapy as a treatment for menopause symptoms such as hot flashes, not for weight. If shifting appetite is tied to the menopause transition, that is worth raising with a clinician who can address both issues appropriately.

The honest cost structure (why there is no single price)

The most misleading thing on any page about these drugs is a single confident dollar figure, because what you actually pay depends on which of several channels applies to you. There is a manufacturer list price, an insured copay if your plan covers the drug, a manufacturer savings card that can lower that copay, a cash self-pay program for people without coverage, and, separately, compounded versions that are not FDA-approved. Each produces a very different number, and all of them change over time.

The table below lays out these channels so you know which one to ask about. For the live figure, use the manufacturer's own page: Lilly publishes Zepbound and Mounjaro pricing and savings terms on its sites, and Novo Nordisk publishes Wegovy and Ozempic pricing through its Save and NovoCare pages. Those are the only authoritative sources for a specific price, and even they note that prices change.

Insurance coverage for weight-management drugs is inconsistent; many plans cover the diabetes indications more readily than the weight ones. Whether a savings card applies often depends on having commercial insurance and an on-label prescription, so eligibility is worth confirming before you commit to a specific drug.

Why OTC and supplement "appetite suppressants" fall short

Walk into any pharmacy or scroll any marketplace and you will find dozens of products labeled as appetite suppressants: glucomannan and other fiber blends, caffeine and green-tea extracts, garcinia cambogia, and proprietary "metabolism" formulas. These are sold as dietary supplements, which means they are not reviewed by the FDA for effectiveness before sale, and the quality evidence that they meaningfully suppress appetite or produce durable weight loss is thin to absent.

Fiber supplements can create a modest feeling of fullness and are generally safe, but that is a small effect, not a substitute for the prescription options. Stimulant-based "fat burners" can raise heart rate and blood pressure and have been linked to adulteration with undeclared drugs in some products, which is a safety concern rather than a benefit.

If you want an appetite intervention with real evidence, the prescription route is where it lives. Spending money on supplements marketed with dramatic before-and-after claims usually buys marketing, not results, and any product promising rapid loss without diet or activity change is signaling that it is not credible.

How to get a prescription legally through telehealth

The legitimate path to any of these medications runs through a licensed prescriber. In a compliant telehealth flow, you complete a medical intake, a clinician licensed in your state reviews your history and eligibility (including the BMI criteria), and if appropriate they send a prescription to a licensed pharmacy that ships an FDA-approved product. No FDA-approved weight medication can be legally bought without a prescription.

A trustworthy provider will screen you out if you do not meet criteria, ask about pregnancy and contraception, review your other medications, and offer follow-up rather than a one-time transaction. Ongoing monitoring matters because doses are titrated and side effects need managing.

Because coverage and pricing vary so much by state and plan, the practical first step is to compare providers licensed in your state, see which drugs each supports, and confirm how they handle insurance versus cash pricing before you start.

Compounded GLP-1s and unapproved online sellers

Compounded semaglutide and tirzepatide are not FDA-approved products. Compounding pharmacies traditionally fill gaps such as drug shortages, and availability of compounded GLP-1s shifted with the branded drugs' shortage status. The FDA has warned about unapproved and compounded GLP-1 products, including dosing errors and products that are not what they claim to be.

Separate from licensed compounding, there is a large gray market of websites selling "semaglutide" or "research peptides" with no prescription, no clinician, and no verified sourcing. These carry real risks of counterfeit or contaminated product, wrong concentrations, and no recourse if something goes wrong. A price that is dramatically below every legitimate channel is a signal of risk, not a bargain.

If cost is the barrier, the safer move is to compare the manufacturer's cash self-pay program and savings card against a legitimate telehealth quote, rather than buying from a seller that skips the prescription entirely.

Frequently asked questions

What is the most effective appetite suppressant for women?

For women who meet the medical criteria, the injectable GLP-1 and dual GIP/GLP-1 drugs Wegovy (semaglutide) and Zepbound (tirzepatide) produce the strongest appetite reduction among current FDA-approved-for-weight options. They slow stomach emptying and act on the brain's appetite signals. The best choice for any individual depends on health history, contraception use, and cost, and should be decided with a prescriber.

Do over-the-counter appetite suppressants work?

OTC appetite suppressants and supplements, such as fiber blends, caffeine, and botanical fat-burners, have little quality evidence that they meaningfully suppress appetite or produce durable weight loss. They are sold as dietary supplements and are not reviewed by the FDA for effectiveness before sale. Fiber can create modest fullness, but that is a small effect compared with the prescription options.

Do I qualify for a prescription appetite suppressant?

The FDA labels for weight-management drugs generally set eligibility at a BMI of 30 or higher, or 27 or higher with at least one weight-related condition such as high blood pressure, type 2 diabetes, or abnormal cholesterol. A licensed prescriber confirms eligibility and reviews your full history. A provider willing to skip this screening is a warning sign.

Can appetite suppressants affect birth control?

Yes, for one of them. The tirzepatide label (Zepbound and Mounjaro) warns that the drug can reduce the effectiveness of oral birth control and advises a backup or non-oral method around starting and dose increases. Semaglutide does not carry this warning. If you use the pill, discuss this difference with your prescriber.

How much do these medications cost?

There is no single price. What you pay depends on the manufacturer's list price, your insurance copay, any manufacturer savings card, or a cash self-pay program, and all of these change over time. Compounded versions are separate and are not FDA-approved. For the current figure, check the manufacturer's own savings page (Lilly for Zepbound and Mounjaro; NovoCare for Wegovy and Ozempic).

Is Ozempic an appetite suppressant for weight loss?

Ozempic contains semaglutide and strongly reduces appetite, but it is FDA-approved for type 2 diabetes, not weight loss, so using it for weight alone is off-label. Wegovy contains the same molecule and is the version FDA-approved specifically for chronic weight management. Off-label status can affect insurance coverage and which savings program you qualify for.

Are compounded semaglutide and tirzepatide safe?

Compounded semaglutide and tirzepatide are not FDA-approved products, and the FDA has warned about unapproved and compounded GLP-1 products, including dosing errors. Availability of compounded versions shifted with the branded drugs' shortage status. Websites selling these without a prescription carry real risks of counterfeit or contaminated product. Comparing a manufacturer cash program against a licensed telehealth quote is the safer route.

Can menopause hormone therapy help with appetite or weight?

No. According to ACOG, menopause hormone therapy is a treatment for menopause symptoms such as hot flashes, not a weight-loss or appetite treatment. If appetite changes are tied to the menopause transition, a clinician can address the menopause symptoms and the weight question separately and appropriately.

Primary sources

1. NIDDK (NIH), Prescription Medications to Treat Overweight & Obesity.
2. FDA Prescribing Information, Wegovy (semaglutide) injection.
3. FDA Prescribing Information, Zepbound (tirzepatide) injection.
4. FDA Prescribing Information, Mounjaro (tirzepatide) injection.
5. FDA Prescribing Information, Ozempic (semaglutide) injection.
6. Lilly, Zepbound coverage & savings.
7. Novo Nordisk, Save on Wegovy.
8. NovoCare, Wegovy cost & coverage.
9. FDA Drugs@FDA approved-drug database (verify a product is FDA-approved).
10. ACOG, Hormone Therapy for Menopause (patient FAQ).